Replimune Raises $55 Million to Advance its Oncolytic Immunotherapy Programs – Markets Insider
|
Replimune Raises $55 Million to Advance its Oncolytic Immunotherapy Programs
Markets Insider He continued, "We view the Replimune management team as the most experienced in the oncolytic immunotherapy field, having developed the first and only oncolytic product to obtain approval by the FDA." Replimune also separately announced today the … Replimune Appoints Howard L. Kaufman, MD, FACS as Chief Medical Officer |
